Migraine: A Disabling Disease and Global Health Problem
Migraines rank as the 3rd most prevalent (and 6th most disabling) illness in the world, affecting 40 million people in the US and 1 billion worldwide. 12% of the population, and 1 in 4 US households, are affected – including 18% of women, 6% of men, and 10% of children. >20% of all migraineurs are disabled, and >4 million adults have migraines daily (or >15 migraines monthly).
Contrary to common public belief, Migraines are more than just headaches. A migraine is almost always associated with other features, including sensitivity to light, sound and smell, nausea, vomiting, and auras. Most migraine sufferers are unable to work, attend to household duties or attend social functions during a migraine attack.
Currently, migraine treatment is dominated by pharmaceutical (drug) approaches and these approaches have been associated with poor outcomes and high rates of dissatisfaction in those who have been tried this approach to the treatment of their migraines.
NOCIRA, LLC, a company I co-founded in 2014 and currently serve on the management team as Chief Scientific Officer and Vice President of Product Development, is conducting an advanced clinical investigation of a new, non-invasive medical device system that is designed to treat migraines by stimulating multiple sensory nerves at the ear to target central pain centers of the brain.
A recent survey conducted by Nocira indicated that most migraine sufferers would prefer to use a device rather than medication or injections, provided it was safe, had few side effects, and was effective. Nocira hopes that our investigational new platform might provide just such a therapy in the future.
CAUTION: INVESTIGATIONAL DEVICE. LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE ONLY.
NOT CE MARKED. NOT AVAILABLE FOR MEDICAL USE IN THE EU UNTIL CE MARK IS COMPLETED.
PATENTED AND PATENT PENDING PRODUCTS AND METHODS. NOCIRA® IS A REGISTERED TRADEMARK OF NOCIRA LLC. COPYRIGHT 2018 © NOCIRA LLC. (ALL RIGHTS RESERVED)